RARA and ovarian carcinoma: It has been documented that CRBP-1 upregulation exerts a direct antitranscriptional effect through the binding of CRBP-1 promoter to RAR-α [135]. In vitro studies confirmed the downregulation of RAR-α and RAR-γ mRNA levels in CRBP-1-stable-transfected ovarian cancer cells [127].